| Purpose:Observed the safety of human umbilical cord blood mononuclear cells transplantation in patients with coronary heart disease and heart failure.Methods: There are total 12 patients(7 Males, 5 Females) with coronary heart disease and heart failure (acute myocardial infarction and heart failure 6 cases, old myocardial infarction and heart failure 6 cases) attending this study, aged 23 ~ 82 (63.83±17.13) years. Patients were treated on the basis of the conventional treatment(standard medication or combining with percutaneous coromary intervention), established the percutaneous catheter of coronary, injected the separation of cord blood mononuclear cells (5.88±2.32)*107through microcatheter into the distal artery. Observed the incidence of adverse reactions including microembolization, arrhythmia, fever, chills, cancer and graft versus host disease. Compared the difference of blood routine, liver function, kidney function, C-reactive protein, IgA, IgG preoperative and postoperative transplantation.Results:1. The incidence of adverse reactions in cord blood stem cell transplantation was 25%(3/12), including arrhythmia 8.3% (1 / 12), fever 16.7% (2 / 12), no micro-embolism, following-up 3-6 months, no tumor and the occurrence of graft-versus-host disease.2. Comparison of preoperative and postoperative transplantation, blood routine, liver function, kidney function, C-reactive protein, IgA, IgG and so on, there is no significant difference (P> 0.05), that is no impact for the blood system, liver, kidney, and immune system.Conclusion: In patients with coronary heart disease and heart failure, human umbilical cord blood monomuclear cells transplation is safe. |
PDF Full Text Request